The prefrontal cortex loses its vote. Reward circuits hijack decision-making, and willpower becomes irrelevant — the brain has been physically restructured to prioritize the substance over everything else.
Detox, then therapy, then hope. MAT (medication-assisted treatment) — methadone, buprenorphine, naltrexone — helps with opioids but doesn't exist for most substances. Behavioral therapies (CBT, motivational interviewing, 12-step) have modest long-term success rates. Relapse rates hover around 40–60% across all substance categories. The brain damage from chronic substance use — prefrontal hypoperfusion, dopamine receptor downregulation, white matter degradation — is rarely treated directly. Recovery programs address behavior while the injured brain struggles to cooperate.
Harch et al. (2017) published in Medical Gas Research a case report showing that HBOT at 1.5 ATA produced significant cognitive improvement and SPECT-confirmed perfusion recovery in a chronic alcohol-dependent patient with brain damage. The patient demonstrated measurable gains in memory, processing speed, and executive function after 40 sessions.1
Shi et al. (2012) demonstrated in Neuroscience Letters that HBOT at 1.5 ATA reduced withdrawal symptoms and drug-seeking behavior in an animal model of morphine dependence. The mechanism involved restoration of dopaminergic signaling in the nucleus accumbens — the same reward circuit disrupted by chronic opioid use.2
Boussi-Gross et al. (2013) showed in PLOS ONE that HBOT at 1.5 ATA restored perfusion to hypoperfused frontal and temporal regions in brain-injured patients, with corresponding improvements in impulse control and decision-making — the exact cognitive capacities that addiction erodes. The findings support HBOT as a tool for rebuilding the prefrontal function that recovery depends on.3
Morries et al. (2015) published in Neuropsychiatric Disease and Treatment a case series showing that transcranial near-infrared light therapy at 810 and 980 nm improved depressive symptoms and cognitive function in patients with TBI — a population with high addiction comorbidity. The prefrontal cortex improvements mapped directly onto the circuits involved in impulse control and reward evaluation.4
Gonzalez-Lima and Barrett (2014) demonstrated in Frontiers in Systems Neuroscience that transcranial infrared stimulation at 1064 nm enhanced prefrontal cortex metabolism and improved sustained attention. Enhanced prefrontal function is the neurobiological prerequisite for overriding compulsive behavior — the core deficit in addiction.5
Cassano et al. (2016) published in Psychological Medicine a study showing that transcranial photobiomodulation at 823 nm significantly improved depression and anxiety scores in patients with major depressive disorder — conditions that drive relapse in over half of recovering addicts. Treating the comorbid mood disorder reduces one of the strongest predictors of return to use.6
Want us to email you when we find new research on addiction treatment?